

Obtaining and Use of Therapeutic Antibodies Entering into the Cell

TECHNICAL FIELD

- 5 The invention relates to the use of therapeutic antibodies entering into the cell. Such therapeutic antibodies would be used for the treatment of cancer and for other applications.

BACKGROUND ART

- 10 All fundamental biological processes, including development, immunity and tumorigenesis, are related to the selective and differential expression of genes in different tissues and cell types. The formation of many malignant tumors has shown to be caused by changes in signals responsible of selective expression of genes. One of the goals of modern molecular medicine is to find the ways of regulating the expression of genes in living
- 15 organisms and developing new treatment strategies on their basis.

- Cancer is the second frequent cause of death in the developed world, thus the keen interest in the molecular mechanisms of the formation of malignant tumors and efficient treatment thereof. The application of complex methods of treatment (combining surgery,
- 20 radiotherapy and cytostatic treatment) have considerably extended the lifespan of patients and improved their quality of life, however, no major breakthrough has been achieved to date. This is why especially the last decade has seen active research into the possibilities of using principally new methods of treatment (biological treatment, gene therapy etc.).

25 DISCLOSURE OF INVENTION

- The limited number of disease-specific cell surface markers is the main problem in immunotherapy. A number of intracellular disease-related molecules have been established and described in detail; unfortunately these are not accessible to the conventional
- 30 antibodies. Our technology enables the use of these intracellular targets and thus to considerably increase the number of specific markers accessible to antibodies. The modified antibodies used by us are not toxic, nor are the component parts used for obtaining such antibodies toxic.

The subject of this invention is a technology for novel (cancer)-specific antibodies entering into the cell. Such antibodies would act by directly modulating the cancer-specific signals. The expected effects and principles of action of such antibodies are inactivation of intracellular proteins, thus these could be used for the treatment of diseases, where the activity of intracellular proteins must be modulated for effective treatment (primarily malignant tumors and diseases, which can be treated by inactivation of intracellular immunogenic therapeutic targets (proteins, glycoproteins etc.)). The above-mentioned antibody technology would also be applied elsewhere (e.g. scientific laboratories that are engaged in investigation of intracellular proteins etc.).

Short overview of technologies

Antibodies

Antibodies are proteins, naturally produced by the immune system as part of the immune response to foreign substances (antigens). Antibodies can be produced against molecule of interest, by using these molecules (or parts of these molecules) as antigens. In biomedicine antibodies that recognise specifically cell surface elements like membrane proteins (receptors) and non-protein components are of special interest as potential drugs. Since these surface markers can be cell type specific, thus it is possible to generate antibodies, which only recognise specific cell type. This feature can be used in the treatment of various diseases: inflammatory diseases, autoimmune diseases (allergic responses), conditions related to the transplantation of tissues, cardiovascular diseases, infectious diseases and primarily various tumors. However, the list should not be seen as an all-inclusive. In the conventional sense antibody therapy does mean the use of antibodies recognising the molecules or cell types causing previously named diseases and conditions.

The technology of generating antibodies is very well described whereas two different strategies exist- monoclonal antibody technology and polyclonal antibody technology. Both types of antibodies are widely used for different research and development purposes. However, such standard antibodies do not have significant potential as therapeutic agents due to their high molecular mass, their inability to enter the cells, their insufficient efficacy of diffusion into the tissues for effective treatment. In addition, standard antibodies are relatively unstable and in some cases non-specific side effects have been observed as well.

Antibodies have been recently expressed intracellularly in several systems to neutralise the function of endogenous target proteins (Ridder *et al.*, 1995). These attempts to use “intrabodies” were made in general by transfection of scFv (single chain fragments variable) expressing vectors, and led to a number of promising results in several fields: cancer, Huntington’s disease, viral diseases (Lecerf *et al.*, 2001; Steinberger *et al.*, 2000; Strube and Chen, 2002). These achievements showed that intracellular expression of antibodies or scFv could efficiently target some proteins and modify the cell’s biology. scFvs - having the VH and the VL domains bridged by a linker peptide - represent the minimal intact binding species of an antibody, and seem to have similar functions as corresponding Fabs. However, the activity of such scFv molecules is greatly limited by their instability and folding efficiency in the reducing intracellular environment. Also, the stability of scFv seems to be dramatically increased when they are engineered as scFvFc (Strube and Chen, 2002). Finally, the delivery of the scFv “intrabodies” remains a problematic issue for their potential therapeutic applications.

We have developed a strategy for resolving these problems; in this patent application we prove the possibilities of implementing these strategies for treatment purposes and other potential applications. We have used the advantage of recent progress in peptide-mediated membrane penetration to directly and efficiently deliver the antibodies or the scFvs to their intracellular target proteins, avoiding the problems of intracellular misfolding in the cellular environment.

Cell Penetrating Peptides

The use of peptide vector molecules (*cell-penetrating peptides*, CPPs) for transporting biologically active molecules has several advantages. It has proved effective in all eukaryotic cells tested so far, which allows them to be used *en masse*. The most recent results permit them also to be used as vectors penetrating the blood-brain barrier (Schwarze *et al.*, 1999).

Transportan is a peptide in which the fragments of the neuropeptide galanin and of mastoparan, a toxic amphiphilic peptide found in wasp venom, are combined. It has been demonstrated that Transportan penetrates cell membranes using nonenzymatic mechanism. After penetration Transportan localises to the cell nucleus, where it further colocalises with

nucleoli. It has been demonstrated both *in vitro* and *in vivo* that various molecules that naturally do not enter the cell (e.g. proteins, peptides, peptide nucleic acids (PNA)) will localise to the nucleus if coupled to transportan (Pooga *et al.*, 1998). Thus Transportan is a suitable transport peptide for transporting proteins, also including antibodies into the cell.

5 Transportan does not cause significant cytotoxic effects. To date a large number of other peptides able to enter the cell have been described, thus our invention can use any such cell penetrating peptide, which is understandable to a person skilled in the art. (Cell Penetrating Peptide; Advances and Applications, Editor Ü. Langel, CRC Press 22).

10 Skin Cancer and GLI Proteins

Skin cancer (both melanomas and forms of non-melanoma skin cancer) is the most common type of cancer in the Western world. Non-melanoma skin cancer has become the second-most common type of skin cancer in women, with its incidence having doubled during the past decade. The main risk factor in both is the ultraviolet radiation. The Basal
15 Cell Carcinoma (BCC) is the most widely spread malignant tumor in the Western world. BCCs can often be treated surgically, therefore the most important result of having a drug to treat this type of tumor would be the increase of cost effectiveness of treatment achieved by avoiding the need for surgery.

20 It has been shown that a large number of both hereditary and sporadic cases of BCC have been caused by mutations in the PTCH gene (human homologue of Drosophila Patched) encoding the receptor of the Sonic hedgehog (Shh) factor that leads to alterations in the signalling pathway mediated by this receptor (Dahmane *et al.*, 1997). The mechanism behind the signalling pathway described above is to control the positioning of cells during
25 embryogenesis. GLI proteins are transcriptor factors that act as effectors of this signalling pathway. GLI proteins interact in the cytoplasm with the protein of the tumor suppressor gene SUFUH (Kogerman *et al.*, 1999) resulting in inactivation of the GLI protein.

Pharmaceutical Composition

30 The present invention is also directed to a pharmaceutical composition, comprising the molecules of the invention in association with pharmaceutically acceptable carriers and additives. Such pharmaceutical composition can be obtained by applying methods and standard materials used in pharmaceutical practice.

Moreover, the present invention is also directed to a method for the treatment of a disease or health disorder in humans or animals. Such method comprises the administration of a pharmaceutically acceptable dose of the invented molecule to humans or animals.

5 The above-mentioned pharmaceutical composition can be administered orally, intravenously or intraperitoneally. The preferred route of administration is intravenous.

BRIEF DESCRIPTION OF THE FIGURES

10 **Figure 1** shows the Transportan TP-10 HPLC chromatogram (figure 1A) and the MALDI-TOF spectrum (figure 1B).

Figure 2 shows the mouse antiGLI IgG-Transportan TP10 conjugate (figure 2A), the mouse FITC-conjugated anti-IgG (figure 2B), the mouse anti-GLI1(IgG)-Transportan
15 TP10 conjugate (figure 2C), the mouse FITC-conjugated anti-IgG (figure 2D).

Figure 3A shows the production and purification of the cell penetrating recombinant protein. The figure shows the image of Coomassie brilliant blue-stained SDS-polyacrylamide gel. Lane 1: molecular weight marker. Lane 2: uninduced *E.coli* cell lysate; Lanes 3
20 and 4: cell lysate, where the expression of the construct has been induced by IPTG. Lanes 5-8: protein fractions 1-4 eluted from glutathione-agarose.

Figure 3B shows the internalisation of the recombinant protein into human 293 cells. The cells were incubated with recombinant proteins and fluorescent anti-GST antibodies (upper
25 image) detected their internalisation into the cells. The image below depicts the phase-contrast image of the same field.

DETAILED DESCRIPTION OF THE INVENTION

30 We have produced monoclonal antibodies against GLI1 and GLI3 proteins. We have conducted preliminary studies and demonstrated that antibodies coupled with cell penetrating transport peptides, are able to effectively penetrate the cell membranes and that

the coupling of such peptides to antibodies does not reduce the ability of the antibodies to recognise specific antigens.

Example 1. Obtaining and characterisation of polyclonal GLI1 antibodies

5 Polyclonal antibodies recognising the GLI1 protein were obtained by immunisation of rabbits by using the GLI1(1-407) antigen expressed in bacteria by using standard methods. The antibodies obtained were characterised by using the Western blot analysis, Electrophoretic mobility shift assay (EMSA) and immunohistochemical methods.

10 Example 2. Obtaining and characterisation of polyclonal GLI3 antibodies

Polyclonal antibodies recognising the GLI3 protein were obtained by immunisation of rabbits by using the GLI3(150-250) antigen expressed in bacteria and by using standard methods. The antibodies obtained were characterised by using the Western blot analysis, Electrophoretic mobility shift assay (EMSA) and immunohistochemical methods.

15

Example 3. Conjugation of peptides entering into the cell to polyclonal GLI1 antibodies

The CPP (Transportan TP10), the shorter analogue of transportan, was synthesised in 0.1 mmol scale on the Applied Biosystem Model 430A peptide synthesizer using the dicyclohexyl carbodimid/hydroxy-benzo-triazole (DCC/HOBT) activation. Peptides were
 20 cleaved from the resin according to the TFMSA cleavage protocol. Resulting peptide was further purified on C₁₈ reversed-phase HPLC column that yielded >99% pure product. The molecular mass of each synthetic peptide was determined by MALDI-TOF mass spectrometry and the obtained result was compared with the calculated molecular mass. Transportan 10 (TP10), the shorter analogue of transportan, was conjugated to polyclonal
 25 antibodies. Figure 1 shows the conjugation of cell penetrating peptides to antibodies, which was carried out as follows:

1) CPP was derivatized into maleimid. SMCC solution (succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate, Mw 334; 1/5 molar ratio) was added to 200 ml of peptide solution in phosphate buffer (ph 7.5; 10 mg peptide/ml). The mixture
 30 described above was incubated for 1-2 hours at room temperature. The SMCC residue was removed by using the HPCL reverse-phase C₁₈ column.

2) In order to deprotect the thiol groups on the antibody, TCEP (tris(2-carboxyethyl)phosphine hydrochloride; Mw 287) in 1/5 molar ratio, was added to the

antibody solution (phosphate buffer, pH 7.5) and the reaction mixture was incubated for 15 minutes.

3) Conjugation of maleimid-derivatized peptide to the antibody. Above-mentioned maleimid-derivatized peptide and antibody solution was combined in an equimolar ratio and incubated at room temperature for 3 hours, yielding a thioester bond between the antibody and the peptide. Resulting preparation was used in further experiments, estimating that the conjugative effect was 80%. Peak 7 corresponded to the calculated molecular mass of TP-10 shown on figure 1A, as demonstrated by the MALDI-TOF mass spectrometry.

The conjugate obtained was able to enter the eukaryotic cells in culture (figure 2). Figure 2A shows the mouse antiGLI IgG-TP10 conjugate incubated for 3 hours with Cos-1 cells; anti-GLI1 IgG visualised with FITC conjugated mouse anti-IgG antibody. Figure 2B shows the mouse FITC conjugated anti-IgG, which was incubated for 3 hours with Cos-1 cells. Figure 2C shows the mouse anti-GLI1(IgG)-TP10 conjugate incubated for 14 hours with Cos-1 cells; anti-GLI1 IgG visualised with FITC conjugated mouse anti-IgG antibody. Figure 2D shows the mouse FITC conjugated anti-IgG, which was incubated for 14 hours with Cos-1 cells. The above-mentioned polyclonal antibodies specifically recognised the GLI 1 protein.

Example 4. Obtaining and characterisation of anti GLI1 monoclonal antibodies

Monoclonal antibodies recognising the GLI1 protein were obtained by immunisation of mice with GLI1(1-407) protein as an antigen. The protein was expressed in bacteria according to the standard protocol (Antibodies: A Laboratory Manual; Ed. Harlow, David Lane; Cold Spring Harbor Laboratory Press, ISBN: 0879693142). The spleens from immunised mice were dissected and the spleen cells were fused with Sp 2.0 myeloma cells by using standard methods (Antibodies: A Laboratory Manual; Ed. Harlow, David Lane; Cold Spring Harbor Laboratory Press, ISBN: 0879693142). Clones from 40 hybridomas were separated. The resulting antibodies were characterised by Western blot analysis, electromobility shift assay (EMSA) and immunohistochemical methods.

Example 5. Obtaining and characterisation of anti GLI3 monoclonal antibodies

Monoclonal antibodies recognising the GLI3 protein were obtained by immunisation of rabbits with GLI3(150-250) antigen. The protein was expressed in bacteria and according to standard methods (Antibodies: A Laboratory Manual; Ed. Harlow, David Lane; Cold Spring Harbor Laboratory Press, ISBN: 0879693142). The resulting antibodies were characterised by Western blot analysis, electromobility shift assay (EMSA) and immunohistochemical methods.

Example 6. Developing a technology for obtaining recombinant cell penetrating proteins

For obtaining a recombinant cell penetrating protein we created expression vector encoding for GST-GLI3(150-250) fusion protein. We used PCR based approach to add the sequences encoding for cell penetrating peptides Transportan TP10 and 9Arg (9Arginine) into previously mentioned vector. These expression constructs were sequenced. Expression of these constructs showed that despite repeated efforts, it was not possible to express a recombinant fusion protein that encoded GST-GLI3(150-250)-Transportan TP10 sequence described above in *E. Coli* system. We succeeded, though, in expressing and purifying a recombinant protein that encoded the recombinant GST-GLI3(150-250)-9Arg cell penetrating peptide (figure 3A).

As we have demonstrated on figure 3B, the obtained recombinant protein entered the cultured mammal cells.

Example 7. Obtaining and characterisation of anti GLI recombinant proteins entering into the cell

The recombinant antibodies were obtained by inserting the sequence encoding for the 9Arg peptide or Transportan or Transportan TP10 into the gene encoding the clones of antibodies described above. The obtained recombinant antibodies were purified using affinity chromatography and antibody titre was determined. We demonstrated that these antibodies were binding specifically to the GLI1 protein. These recombinant antibodies also entered into the eukaryotic cells in culture.

In order to obtain the scFv with ability to penetrate into the cell we made a construct encoding for single chain antibody, or scFv, containing the two variable domains of an

antibody molecule (the VL and the VH domain) linked via flexible peptide linker that also contained the sequence of CPP. The RNAs from the anti GLI1 and 3 monoclonal antibodies were reverse transcribed and this first cDNA strand was used as a template for variable regions amplification using degenerated primers:

5

T A/C A C C A T G G G A T G G A G A/C T G G A

ATTATCACTGGGTCACCTTGAC

TGACAGGCTGGGCTGGCAGGA

A G C/T C T C C C C C/G A/T G G/A G/C C/T T

10

C T T G C A C A G A/T A A T A C A

GAGCTCGTGATGACCCAGTCTCCA

T T C C A G C T T G G T C/G C C A/G C C A/T

AACACTCATTCCTGTTGAAGC

15

PCR products of the appropriate size (320-350 bp) were purified and sequenced. Oligonucleotide primer encoding for Transportan or Transportan TP10 and linker (Gly4Ser)₃ was used to construct a VL-TP-Linker-VH sequence by three-step overlap extension PCR. The process was repeated for scFvFc construction with relevant VLCL and VHCH1 PCR products. The final PCR products corresponding scFv and scFvFc (both with
20 CPP and linker encoding) sequence were cloned into eukaryotic expression vector (pcDNA3, pCEP) and sequenced. Eucaryotic cells (Cos-7) were be transfected with scFv or scFvFc constructs and according to the manufacturer's instructions for generation of stable cell lines. Recombinant proteins were purified from supernatant using Ni⁺ columns.

25

References:

Dahmane, N., Lee, J., Robins, P., Heller, P., and Ruiz i Altaba, A. (1997). *Nature* **389**, 876-81.

Kogerman, P., Grimm, T., Kogerman, L., Krause, D., Unden, A. B., Sandstedt, B., Toftgard, R., and Zaphiropoulos, P. G. (1999). *Nat Cell Biol* **1**, 312-9.

30

Lecerf, J. M., Shirley, T. L., Zhu, Q., Kazantsev, A., Amersdorfer, P., Housman, D. E., Messer, A., and Huston, J. S. (2001). *Proc Natl Acad Sci U S A* **98**, 4764-9.

Pooga, M., Soomets, U., Hallbrink, M., Valkna, A., Saar, K., Rezaei, K., Kahl, U., Hao, J. X., Xu, X. J., Wiesenfeld-Hallin, Z., Hokfelt, T., Bartfai, T., and Langel, U. (1998). *Nat Biotechnol* **16**, 857-61.

Ridder, R., Schmitz, R., Legay, F., and Gram, H. (1995). *Biotechnology (N Y)* **13**, 255-60.

- 5 Schwarze, S. R., Ho, A., Vocero-Akbani, A., and Dowdy, S. F. (1999). *Science* **285**, 1569-72.

Steinberger, P., Andris-Widhopf, J., Buhler, B., Torbett, B. E., and Barbas, C. F., 3rd. (2000). *Proc Natl Acad Sci U S A* **97**, 805-10.

Strube, R. W., and Chen, S. Y. (2002). *J Immunol Methods* **263**, 149-67.

Claims

1. Use of a molecule comprising at least a sequence of the antibody recognising the antigen and a cell penetrating transport peptide for the preparation of a medicament for the treatment of a disease or health disorder.
2. Use as claimed in claim 1 characterised in that the molecule is a monoclonal antibody to which a cell penetrating transport peptide has been chemically conjugated.
3. Use as claimed in claim 1 characterised in that the molecule is a polyclonal antibody to which a cell penetrating transport peptide has been chemically conjugated.
4. Use as claimed in claims 2 and 3 characterised in that the monoclonal or polyclonal antibodies have been obtained against the GLI1 protein.
5. Use as claimed in claims 2 and 3 characterised in that the monoclonal or polyclonal antibodies have been obtained against the GLI3 protein.
6. Use as claimed in claim 1 characterised in that the molecule comprises a variable sequence of the genetically modified antibody, to which a cell penetrating transport peptide necessary for entering into the cell has been conjugated or has been included in another manner in the sequence thereof.
7. Use as claimed in claim 6 characterised in that the variable sequence of the genetically modified antibody is derived from the human genome.
8. Use as claimed in claim 7 characterised in that the variable sequence of the human genetically modified antibody is obtained by immunisation with an antigen of a transgenic animal having the humanised immune system.
9. Use as claimed in claim 7 characterised in that the variable sequence of the genetically modified antibody is obtained by screening the human antibody expression library with antigen.

10. Use as claimed in claims 7 to 9 characterised in that the GLI1 sequences are used as antigen.
11. Use as claimed in claims 7 to 9 characterised in that the GLI3 sequences are used as antigen when screening the human antibody expression library.
12. Use as claimed in claims 1 to 11 characterised in that the peptide sequence entering into the cell is Transportan TP10.
13. Use as claimed in claims 1 to 11 characterised in that the peptide sequence entering into the cell is a peptide comprising 9 Arginine.
14. Use as claimed in claims 1 to 13 characterised in that any intracellular therapeutic target is used as antigen.
15. A pharmaceutical composition comprising at least one molecule as defined in claims 1 to 14 in association with at least one pharmaceutically acceptable carrier or additive.
16. A method for obtaining a recombinant polypeptide comprising an encoding sequence of the said polypeptide and the sequence of a cell penetrating transport peptide, expression of the recombinant protein in a suitable host organism and purification of the obtained protein.

Abstract

The invention relates to the development of a novel technology of (cancer-) specific antibodies entering into the cell and their use for treatment of human diseases (primarily cancer). Such antibody (drug) would act by directly modulating the cancer-generating signals. The expected effects and principles of action of such antibodies are inactivation of intracellular proteins and thus they could be used for the treatment of diseases, where the activity of intracellular proteins must be modulated for effective treatment (primarily malignant tumors, but also many other diseases, which can be treated by inactivation of intracellular proteins). Above-mentioned antibody technology would also be applied elsewhere (e.g. scientific laboratories, that are engaged in investigation of intracellular proteins etc).

ATT253166.txt
SEQUENCE LISTING

<110> INBIO OÜ

<120> OBTAINING AND USE OF THERAPEUTIC ANTIBODIES ENTERING INTO THE CELL

<130> 1352/4381

<140> PCT/EE2003/000005

<141> 2003-09-16

<150> EE P200200531

<151> 2002-09-17

<160> 8

<170> PatentIn version 3.1

<210> 1

<211> 23

<212> DNA

<213> Mus musculus

<400> 1

tacaccatgg gatggagact gga

23

<210> 2

<211> 21

<212> DNA

<213> Mus musculus

<400> 2

attatcactg ggtcacttga c

21

<210> 3

<211> 21

<212> DNA

<213> Mus musculus

<400> 3
tgacaggctg ggctggcagg a

21

<210> 4

<211> 22

<212> DNA

<213> Mus musculus

<400> 4
agctctcccc cgatggagcc tt

22

<210> 5

<211> 17

<212> DNA

<213> Mus musculus

<400> 5
cttgcacaga taataca

17

<210> 6

<211> 24

<212> DNA

<213> Mus musculus

<400> 6
gagctcgtga tgaccagtc tcca

24

<210> 7

<211> 22

<212> DNA

<213> Mus musculus

<400> 7
ttccagcttg gtcgccagcc at

22

<210> 8

<211> 21

<212> DNA

<213> Mus musculus

<400> 8

aacactcatt cctgttgaag c

21

1/4




FIGURE 1A




FIGURE 1B

2/4




FIGURE 2A




FIGURE 2B

3/4




FIGURE 2C




FIGURE 2D

4/4





FIGURE 3A
Fluorescent



Phase contrast



FIGURE 3B